On January 12, 2026 Infinitusbio.AI, a U.S.-based Pharmatech company and creator of the proprietary Simulative AI Digital Cell Clone platform, and Oncovita, a Paris-based biotechnology company spun out of the Institut Pasteur and specialized in in situ cancer immuno-oncolytic virotherapy, announce a strategic partnership aimed at accelerating the development of next-generation cancer immunotherapies while creating long-term value for both companies. The partnership follows infinitusbio.AI’s successful Digital Cell Clone simulations using Oncovita’s vaccine candidates, which confirmed the wet‑lab results generated by Oncovita.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On the J.P. Morgan Healthcare Conference, held in San Francisco from January 12 to 15, Stéphane Altaba, CEO, and Patrick Spies, CFO of Oncovita, will present the company and this new partnership with infinitusbio.AI during a SimulativeBio session hosted at PricewaterhouseCoopers LLP on Wednesday, January 14, from 3:30 p.m. to 7:00 p.m. (PST). The session will explore the theme: "Cells, Machines, and the Future of Pharma: The case for simulative AI as the viable approach to modeling complex biological systems at scale."

In addition, Oncovita will present its strategy and latest developments at the RESI Conference on Tuesday, January 13 at 4:00 p.m. (PST) at the Marriott Marquis Hotel, San Francisco.

A strategic partnership to optimize the development of new therapeutics candidates from its Measovir platform.
This collaboration combines infinitusbio.AI’s unique Simulative AI Digital Cell Clone platform with Oncovita’s deep expertise in developing new cancer treatments based on genetically modified Measles vaccine virus, creating a powerful engine for faster, more cost‑efficient advancement of new oncology therapies.
The partnership will leverage infinitusbio.AI’s Digital Cell Clone platform, which can directly incorporate real‑world patient data to strengthen the IND‑enabling process by integrating it with animal testing results.
Oncovita’s Measovir proprietary platform enables the creation of customized therapeutic candidates based on the safe and lifelong protective measle vaccine to target solid tumor cancers. infinitusbio.AI will support Oncovita in selecting additional cancer indications for its current candidate MVdeltaC and suitable payloads for its future candidates, enabling efficient expansion of Oncovita’s drug pipeline and enhancing the company’s overall value.

« We’re delighted to enter this collaboration and advance our next generation immunotherapy programs with the support of infinitusbio.AI’s Digital Cell Clone platform. The partnership follows infinitusbio.AI’s successful Digital Cell Clone simulations using Oncovita’s vaccine candidates, which confirmed the wet‑lab results generated by Oncovita. Integrating infinitusbio.AI’s unique capabilities into our research aligns perfectly with our commitment to adopting smarter, more efficient R&D practices. This partnership will help us broaden the applicability of our Measovir platform to address additional cancer types, design new payloaded-engineered candidates and significantly shorten the time needed to deliver new therapies to patients.", said Stephane Altaba, CEO of Oncovita.

"We are very pleased to begin this strategic partnership with Oncovita, an exceptionally innovative French biotech company. We believe the combination of infinitusbio.AI’s Digital Cell Clones Lab platform and Oncovita’s deep expertise in immune-onco virotherapy will clearly demonstrate the transformative power of Simulative AI—from accelerating disease‑target discovery to optimizing clinical trial design. As we look ahead to an exciting 2026, we are confident this collaboration will drive meaningful progress in Oncovita’s next generation immunotherapy treatment development for the benefit of patients," explains Khai Pham, Founder & CEO of infinitusbio.AI.

Oncovita’s development strategy includes combination‑therapy to enhance efficacy in specific clinical settings. infinitusbio.AI’s platform can accelerate this exploration without requiring a dedicated training dataset, using its Human Cell Intelligent Model that can auto‑differentiate into any digital cell clone within minutes to infer potential outcomes.
infinitusbio.AI’s mechanistic digital cell clones will play a key role in validating the mechanism of action of Oncovita’s next generation immunotherapy, providing deeper insights into its biological efficacy. infinitusbio.AI’s digital cell clones will enable comparative analyses, helping Oncovita evaluate its cancer immunotherapy against existing cancer therapies.
The collaboration will also support Oncovita in identifying predictive biomarkers that can guide patient selection and improve clinical success.

(Press release, Oncovita, JAN 12, 2026, View Source [SID1234662042])

On January 12, 2026 Bio‑Sourcing and Zerion Pharma A/S reported that their joint project to develop an oral formulation of Trastuzumab, the pioneer monoclonal antibody used to treat breast cancer, has been awarded funding under EUREKA Eurostars. This is Bio‑Sourcing’s second Eurostars success and, together with Zerion’s breakthrough Dispersome technology, it will support the development of an oral formulation of an anti‑HER2 antibody for the treatment of HER2‑positive breast cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The program brings together Bio‑Sourcing’s disruptive BioMilk platform—which leverages natural milk components to protect and transport biologics through the gastrointestinal tract and has already been used to produce TrastuzOral —and Zerion’s solid oral‑dosage capabilities using its protein‑based Dispersome technology. Over 36 months, the consortium will optimize an orally deliverable trastuzumab biobetter produced in goat’s milk and progress it through preclinical validation, with the ambition to prepare for entry into Phase I clinical studies around 2030. The total project budget is €1.3 million, with Bio‑Sourcing as lead and Zerion as partner.

An effective oral therapy for HER2 breast cancer has the potential to move care beyond infusion centers, improving patient convenience and adherence while reducing pressure on healthcare resources. The differentiated oral route offers a compelling value proposition in a mature trastuzumab market and creates a platform opportunity to expand oral delivery to other biologics. With the global trastuzumab market estimated at $4.1 billion by 2030, an orally delivered formulation offers clear differentiation and the potential to both capture a significant share of this demand as well as increase overall market size.

Bertrand Mérot, CEO of Bio‑Sourcing: "We are delighted and very proud of Eurostars’ confirmation of the relevance of our unique strategy for oral administration of monoclonal antibodies. I am confident that our partnership with Zerion will further accelerate the development and commercialization of this disruptive formulation for breast cancer. Bio-Sourcing is thus continuing its strategy of developing oral administration of monoclonal antibodies, which has already led to the production of OralimuMab and TrastuzOral in a synergistic partnership with Zerion to further enhance this paradigm shift. The development of this breakthrough in the systemic oral administration of monoclonal antibodies will not only greatly improve patient comfort but also increase access to these innovative treatments, thereby significantly expanding the biopharmaceutical markets."

Ole Wiborg, CEO of Zerion Pharma A/S: "We are excited and very pleased to obtain this Eurostar grant together with Bio-Sourcing. I believe that our joint project holds a significant promise for improving the treatment of breast cancer patients and will further open up a plethora of additional opportunities for switching injectables to orally administered drugs. This blue stamping from EUREKA is also another recognition of our Dispersome technology and our excellent team of scientists that has relentlessly transformed great academic science into a commercially successful technology. I am grateful for that."

Eurostars forms part of the Horizon Europe framework and supports innovative SMEs and project partners—including universities and research organizations—through funding for international collaborative R&D and innovation projects. It is managed by EUREKA, an intergovernmental network covering 37 countries.

(Press release, Zerion, JAN 12, 2026, View Source [SID1234662004])

On January 12, 2026 TriSalus Life Sciences, Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, reported preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company anticipates fourth quarter 2025 revenues of approximately $13.2 million and full-year 2025 revenues of approximately $45.2 million. As of December 31, 2025, TriSalus estimates cash and cash equivalents of approximately $20.4 million.

"TriSalus continued to deliver strong commercial performance in the fourth quarter and exceeded our 2025 guidance of 50% annual revenue growth, underscoring the meaningful clinical adoption of our TriNav product suite and proprietary PEDD platform across a broad range of solid tumor indications," said Mary Szela, President and Chief Executive Officer of TriSalus. "We are pleased not only with our commercial execution but also with the sustained progress on our strategic initiatives, including expansion of the TriNav platform across multiple indications beyond the liver and deepening our engagement within the interventional radiology community. Looking ahead to 2026, we expect full-year revenues to be in a range of approximately $60 million to $62 million."

Projected Unaudited 2025 Fourth Quarter and Full-Year Financial Results

Preliminary revenue for the fourth quarter of approximately $13.2 million, compared to $8.3 million in the prior year, representing approximately 60% growth year-over-year and sequential quarterly growth of approximately 14%.
Preliminary revenue for the year of approximately $45.2 million for the year, compared to $29.4 million in the prior year, representing approximately 53% growth year-over-year.
Year-end cash and cash equivalents of approximately $20.4 million, compared to $22.7 million at the start of the fourth quarter, a reduction in cash and cash equivalents for the fourth quarter of 2025 of $2.3 million. This reflects continued strong revenue growth and focus on operational efficiency.
The preliminary financial results set forth above are unaudited, are based on management’s initial review of TriSalus Life Science’s results as of and for the year ended December 31, 2025, and are subject to revisions based upon TriSalus Life Science’s year-end closing procedures and the completion of the external audit of TriSalus Life Science’s year-end financial statements. Actual results may differ materially from these preliminary unaudited results as a result of the completion of year-end closing procedures, final adjustments and other developments arising between now and the time that TriSalus Life Science’s financial results are finalized. In addition, these preliminary unaudited results are not a comprehensive statement of TriSalus Life Science’s financial results for the year ended December 31, 2025, should not be viewed as a substitute for full, audited financial statements, prepared in accordance with generally accepted accounting principles, and are not necessarily indicative of the Company’s results for any future period. Accordingly, investors are cautioned not to place undue reliance on these preliminary unaudited results.

TriSalus Life Sciences expects to announce full-year 2025 financial results its during earnings conference call in March 2026.

(Press release, TriSalus Life Sciences, JAN 12, 2026, View Source [SID1234662003])

On January 12, 2026 Ono Pharmaceutical Co., Ltd. (TSE:4528) reported that Toichi Takino, President and COO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 11:15 a.m. PST / 2:15 p.m. EST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the event will be available here and accessible for 30 days following the presentation.

(Press release, Ono, JAN 12, 2026, View Source [SID1234662002])

On January 12, 2026 Novocure (NASDAQ: NVCR) reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Novocure exits 2025 having achieved record annual revenue, providing the financial strength to execute on the exciting growth opportunities we have in 2026," said Frank Leonard, CEO, Novocure. "We have built the team and capabilities to support multiple product launches in the coming year while ensuring the company is on a clear path to profitability."

Financial updates for the year and fourth quarter ended December 31, 2025*:

Total preliminary net revenues for the year were $655.4 million, an increase of 8% compared to the prior year.
Total preliminary net revenues for the fourth quarter were $174.4 million, an increase of 8% compared to the same period in 2024.
The U.S., Germany, France and Japan contributed $101.6 million, $21.6 million, $20.5 million and $10.2 million in net revenue, respectively, with other active markets contributing $15.8 million.
Revenue in Greater China from Novocure’s partnership with Zai Lab totaled $4.6 million.
Recognized revenue from Optune Lua in the quarter was $3.5 million, including $2.4 million from non-small cell lung cancer (NSCLC) and $1.1 million from malignant pleural mesothelioma (MPM).
Cash, cash equivalents and short-term investments were $448.3 million as of December 31, 2025, after repayment of $561 million of convertible notes at maturity in November 2025.
Operational updates for the year and fourth quarter ended December 31, 2025:

As of December 31, 2025, there were 4,620 total active patients on TTFields therapy globally.
Optune Gio
1,609 Optune Gio prescriptions for the treatment of glioblastoma (GBM) were received in the quarter, an increase of 6% from the same period in 2024. The U.S., Germany, France and Japan contributed 950; 178; 197 and 139 prescriptions, respectively, with the remaining 145 prescriptions received from other active markets.
As of December 31, 2025, there were 4,464 active Optune Gio patients on therapy, an increase of 9% from the same period in 2024. The U.S., Germany, France and Japan contributed 2,251; 623; 509 and 542 Optune Gio active patients, respectively, with the remaining 539 active patients contributed by other active markets.
Optune Lua
145 total prescriptions for Optune Lua were received in the quarter.
118 Optune Lua prescriptions were received for the treatment of NSCLC. The U.S., Germany and France contributed 87; 29 and 1 prescriptions, respectively, with the remaining 1 prescription received from other active markets.
27 Optune Lua prescriptions were received for the treatment of MPM. The U.S. and Germany contributed 10 and 16 prescriptions, respectively, with the remaining 1 prescription received from other active markets.
As of December 31, 2025, there were 122 active Optune Lua patients on therapy for the treatment of NSCLC. The U.S. and Germany contributed 102 and 19 active patients, respectively, with the remaining 1 active patient contributed by other active markets.
As of December 31, 2025, there were 34 active Optune Lua patients on therapy for the treatment of MPM. The U.S. and Germany contributed 8 and 24 active patients, respectively, with the remaining 2 active patients contributed by other active markets.
In Q1 2026, Novocure intends to stop reporting new prescriptions received in indications which have been commercially available for more than one year (GBM, MPM and NSCLC). Novocure will continue to report active patients on therapy segmented by product (Optune Gio, Optune Lua) and material market.
Fourth quarter and recent updates and achievements:

In December, Novocure announced the appointment of Frank Leonard as Chief Executive Officer. Mr. Leonard previously served as Novocure’s President.
In December, Novocure submitted the final module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for TTFields therapy use for the treatment of brain metastases from NSCLC.
Anticipated clinical and regulatory milestones:

Topline data from the Phase 2 PANOVA-4 clinical trial in metastatic pancreatic cancer (Q1 2026).
Topline data from the Phase 3 TRIDENT clinical trial in newly diagnosed GBM (Q2 2026).
Decision by the U.S. FDA on the PMA application for the use of TTFields therapy for the treatment of locally advanced pancreatic cancer (Q2 2026).
Decision by the U.S. FDA on the PMA application for the use of TTFields therapy for the treatment of brain metastases from NSCLC (Q4 2026).
Complete enrollment in Phase 3 KEYNOTE D58 clinical trial in newly diagnosed GBM (Q4 2026).
Active Patients on Therapy

December 31,

2025

2024

Optune Gio

Optune Lua

Total

Optune Gio

Optune Lua

Total

Active patients at period end1

United States

2,251

110

2,361

2,161

31

2,192

International markets:

Germany

623

43

666

564

11

575

France

509

—

509

426

—

426

Japan

542

—

542

420

—

420

Other international

539

3

542

506

7

513

International markets – Total

2,213

46

2,259

1,916

18

1,934

4,464

156

4,620

4,077

49

4,126

Fourth quarter and full year 2025 financial results conference call:

Novocure will host a conference call and webcast to discuss full year and fourth quarter 2025 financial results at 8:00 a.m. EST on Thursday, February 26, 2026. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link.

The webcast, earnings slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for at least 14 days following the call. Novocure has used, and intends to continue to use, its investor relations website, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

*The unaudited financial results and other data in this press release are preliminary and subject to the completion of the Company’s annual independent audit and final review and, therefore, are subject to adjustment.

(Press release, NovoCure, JAN 12, 2026, View Source [SID1234662001])